Betamethasone Phonophoresis For Vitiligo

NCT07267273 | Recruiting DMC

• 1 other identifier: Treatment of Vitiligo
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin. Vitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease. Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients . Now days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.

Conditions

Vitiligo

Outcome Measures

Primary Outcomes (1)

• vitiligo Management

  Evaluation of the patients whom suffering from vitiligo and using betamethasone phonophoresis for the treatment of vitiligo using Vitiligo noticeability scale (VNC)

  3 Months

Study Arms (2)

Patients Group

ACTIVE COMPARATOR

This group of patients composed of 30 Male and female patients who received betamethasone cream then after 20 minutes ultrasound was applied, three times per week for 1 month.

Drug: Beclomethasone

Control Group

ACTIVE COMPARATOR

This group of patients composed of 30 Male and female patients who received ultrasound then after 20 minutes patients received betamethasone cream, three times per week for 1 month.

Drug: Beclomethasone

Interventions

Beclomethasone DRUG

to determine the effect of betamethasone phonophoresis on vitiligo patients.

Also known as: phonophoresis

Control Group; Patients Group

Eligibility Criteria

• Age: 25 Years - 40 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female patients diagnosed with vitiligo.
• Medically and psychologically stable patients.
• Good cognitive abilities to understand the requirements of the study.
• All patients enrolled to the study will have their informed consent.
• they had no contraindications to the use of therapeutic ultrasound

You may not qualify if:

• Pregnancy or lactation.
• Immunosuppression.
• Alcohol abuse.
• History of spontaneous re-pigmentation of lesions.
• Presence of skin characteristics that may interfere with study assessment.
• Active bacterial/viral infection.
• Patients on other immune suppressants and phototherapy
• Patients currently participating in any other clinical study
• Uncooperative patients.

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Cairo University Hospital

Cairo, Egypt

RECRUITING

MeSH Terms

Conditions

Vitiligo

Interventions

Beclomethasone; Phonophoresis

Condition Hierarchy (Ancestors)

Hypopigmentation; Pigmentation Disorders; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Chlorinated; Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Nisreen Afify Abd-Elrasheed, Professor

  Physical Therapy for Surgery,Faculty of Physical Therapy,Cairo University

  STUDY CHAIR

Central Study Contacts

Ola Sabry Abd-Elmaksoud Tarabya, MSc

CONTACT

+201024035447; Olasabry17@yahoo.com

Nisreen Afify Abd-Elrasheed, Professor

CONTACT

+201143872680; Nessrien.afify@pt.cu.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident at Physical Therapy for Surgery

Study Record Dates

• First Submitted: November 23, 2025
• First Posted: December 5, 2025
• Study Start: November 10, 2025
• Primary Completion: February 1, 2026
• Study Completion: February 10, 2026
• Last Updated: December 5, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)